Nasdaq Alert (CRDL) Goes Green (Pushes Through $1.00 Level Early - Triggered Technicals)

CRDL needs to be on immediate breakout watch. Here's why. Nasdaq Alert (CRDL) Goes Green (Pushes Through $1.00 Level Early - Triggered Technicals) September 21st Dear Reader, CRDL needs to be on immediate breakout watch. Here's why. First off, the technicals on CRDL are triggered bullishly. A whole bunch as a matter of fact. Take a look at the 10+ triggered over at [Barchart]( across the short, medium, and long term. Plus, the company rolled out this major announcement recently: [Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis]( And with a quick green push over $1.00 this morning, psychological resistance at that level could be breaking down (which could be huge for continued vertical momentum). Take a moment to review my initial CRDL report below and get this Nasdaq profile on radar quickly. ----- It's absolutely imperative to keep a hawk-eyed focus on any company delving into the fight against inflammation and fibrosis in heart diseases while pioneering therapies. Why? Because heart diseases, including Pericarditis, Myocarditis, and Heart Failure, are vicious adversaries, relentlessly wreaking havoc on countless lives. Understanding the ruthless role that inflammation and fibrosis play in these conditions is not just a luxury; it's a dire necessity to combat this silent assassin effectively. These heart conditions are insidious, sharing malevolent pathological mechanisms rooted in inflammation and fibrosis. A company laser-focused on cracking this code has the potential to unleash revolutionary treatments, shifting the balance of power in our favor. Oh yeah... Don't get me started on the Inflammasome – that's the enemy within, a relentless adversary in the realm of the immune system. Targeting it could be the game-changer, not only for heart diseases but for an array of inflammatory afflictions. And right now, one company flying below Wall Street's radar may hold the keys to a brighter, healthier future in the relentless battle against heart diseases. Add in that [Barchart]( is reporting this breakout idea to have 10+ triggered technical indicators and that this profile closed above [3 key technical lines]( Wednesday, and you'll understand why you need to drop everything and pull up: *Cardiol Therapeutics Inc. (CRDL)* Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx™ (cann-a-bidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. And right now CRDL has several must-know potential catalysts that could provide it with a near term breakout spark. Check them out: No. 1 - Technical Indicators Triggered Bullish (10+ In All!) No. 2 - CRDL Plans To Reach Crucial Milestone Up To 6 Months Early No. 3 - Analysts Provide Positive Sentiment With Strong Price Targets No. 4 - Could Key Chart Support Be Growing At Multiple Levels? But more on those in a second... Cardiol's Immediate Focus The company is focused on understanding how inflammation and fibrosis contribute to diseases of the heart and to develop therapies, now in clinical trials for rare cardiac conditions, to target these mechanisms and promote healing. Pericarditis Pericarditis is the most common form of pericardial disease with a prevalence of 160,000 in the United States; following an initial episode, 15 – 30% of patients experience a recurrence. Pericarditis refers to inflammation of the membrane or sac that surrounds the heart (the pericardium) that is most frequently triggered from a viral infection. Recurrent pericarditis is the most common complication following an initial acute episode of pericarditis, and patients may have multiple recurrences. Symptoms include debilitating chest pain, shortness of breath, and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Infrequent but life-threatening complications associated with pericarditis include a large accumulation of pericardial fluid, scarring, and constriction of the heart which may limit heart function. The disease is diagnosed in 0.2% of all cardiovascular in-hospital admissions and is responsible for 5% of emergency room admissions for chest pain in North America and Western Europe. Cardiol is conducting a Phase II open-label pilot study (MAvERIC-Pilot) designed to evaluate the tolerability, safety, and efficacy of their lead investigational drug, CardiolRx™, in patients with recurrent pericarditis. The study will also assess the improvement in objective measures of disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids, while taking CardiolRx™. ----- Myocarditis Acute myocarditis is a leading cause of sudden cardiac death in people under 35 years of age. Myocarditis is an acute inflammatory condition of the heart muscle (myocardium) characterized by chest pain, impaired cardiac function, atrial and ventricular arrhythmias, and conduction disturbances. Although the symptoms are often mild, myocarditis remains an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people under 35 years of age. Although viral infection is the most common cause of myocarditis, the condition can also result from bacterial infection, commonly used drugs and mRNA vaccines, as well as therapies used to treat several common cancers, including chemo-therapeutic agents and immune checkpoint inhibitors. CardiolRx™ is currently being evaluated in a Phase II multi-national study (ARCHER) to evaluate its safety and tolerability as well as its impact on myocardial recovery, in patients presenting with acute myocarditis. ARCHER is expected to enroll 100 patients at major cardiac centers in North America, Europe, Latin America, and Israel. ----- Heart Failure Heart failure affects more than 64 million people globally and associated healthcare costs exceed $30Bn annually in the U.S. alone. Heart failure is a chronic, progressive syndrome in which the heart muscle is unable to pump enough blood to meet the body’s needs for blood and oxygen. People with heart failure suffer from shortness of breath, rapid heart rate, edema, reduced exercise capacity, often struggle with simple daily activities, and are frequently hospitalized. For many, these symptoms significantly reduce their quality of life. Known causes of heart failure include ischemic heart disease and myocardial infarction (heart attack), hypertension, valvular heart disease, inflammatory diseases of the heart such as myocarditis and cardiomyopathies, anti-cancer therapies, and inherited metabolic diseases. CRD-38 is their novel proprietary drug formulation designed to deliver cann-a-bidiol by subcutaneous administration. They are undertaking IND-enabling activities to support clinical evaluation of CRD-38 as a therapeutic strategy in heart failure care. ----- The Inflammasome Inflammasomes are large, intracellular, multiprotein, sensor complexes which under normal conditions are essential to innate immunity and maintaining homeostasis. The NLRP3 (NACHT, leucine-rich repeat, and pyrin domain-containing protein 3) inflammasome is the most extensively studied. Aberrant activation of inflammatory pathways, including the NLRP3 inflammasome, occurs under various conditions such as obesity, hypertension, diabetes, and autoimmunity, or in response to a trigger (e.g., viral infection). This activation contributes to the release of cytokines (IL-1β; IL-6; IL-18) and mechanisms (pyroptosis; endothelial dysfunction) which lead to a cycle of inflammation and fibrotic responses. These responses are associated with contributing to the pathogenesis and progression of heart diseases including pericarditis, myocarditis, and heart failure. The exact mechanism by which their investigational drugs inhibit inflammation and fibrosis is not fully elucidated; however, their research and that of others suggests that the active pharmaceutical ingredient in CardiolRx™ and CRD-38 attenuates multiple inflammatory signaling pathways, including inhibiting activation of the NLRP3 inflammasome. By targeting inflammatory signaling pathways, their approach has therapeutic potential to heal the heart. ----- Product Pipeline Major Milestones Sources: [Company Website.]( [Company Presentation.]( ----- As mentioned above, CRDL has several potential catalysts that could be painting a target on this Nasdaq profile. Here they are: No. 1 CRDL Potential Catalyst - Technical Indicators Triggered Bullish (10+ In All!) I'm telling you right now... Don't discount CRDL's bullish technical indicators. At close Wednesday, CRDL was displaying several triggered technical indicators across the short, medium term, and long term. [Barchart]( was reporting these as triggered: Short Term Indicators - 20 Day Moving Average - 20 - 50 Day MACD Oscillator - 20 - 100 Day MACD Oscillator - 20 - 200 Day MACD Oscillator Medium Term Indicators - 50 Day Moving Average - 50 - 100 Day MACD Oscillator - 50 - 150 Day MACD Oscillator - 50-200 Day MACD Oscillator Long Term Indicators - 100 Day Moving Average - 150 Day Moving Average - 200 Day Moving Average - 100 - 200 Day MACD Oscillator The website also shares its all-important "Trend Seeker" composite indicator is triggered. Watch these technicals closely this week. ----- No. 2 CRDL Potential Catalyst - CRDL Plans To Reach Crucial Milestone Up To 6 Months Early Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule Multi-Center, International, Double-blind, Placebo-controlled Trial Randomizing 100 Patients Toronto, Ontario--(Newsfile Corp. - September 19, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announces that all collaborating research centers have been initiated and are eligible to enroll patients in ARCHER, the Company's Phase II, multi-center, international, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRx™, as well as its impact on myocardial recovery, in patients presenting with acute myocarditis. ARCHER is expected to enroll 100 patients at major cardiac centers in North America, Europe, Latin America, and Israel. "Initiation of all clinical research centers coupled with the current rate of randomizations, as well as an expected increase in acute myocarditis cases as the northern hemisphere enters the viral infection seasons of autumn and winter, provide us a high degree of confidence to forecast that ARCHER will complete full patient enrollment ahead of schedule," commented Dr. Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer and Head of Research & Development. "This is a significant milestone in expanding the reach of ARCHER worldwide and contributing to evaluating the clinical potential of CardiolRx™ in acute myocarditis, an inflammatory condition of the heart muscle characterized by chest pain, impaired heart function, arrhythmias, and conduction disturbances. The data generated from patients who enroll in ARCHER will provide important information in support of the use of CardiolRx™ as a novel small molecule therapeutic approach for this debilitating rare disease, which is an important cause of acute and fulminant heart failure and a leading cause of sudden cardiac death in people under 35 years of age, for which there are no approved therapies." ... [Read the full article here.]( ----- No. 3 CRDL Potential Catalyst - Analysts Provide Positive Sentiment With Strong Price Targets Take a look at this: [(Source)]( Those are two targets providing triple-digit potential upside from CRDL's closing valuation on Wednesday. And even better, Edward Nash of Canaccord Genuity actually bumped his target up to $6.00 in a bullish move. Could more analysts see CRDL as an undervalued company ahead of 2024? With CardiolRx™ already being evaluated in a Phase II multi-national study (ARCHER), it makes CRDL a Nasdaq profile worth watching closely at current levels. ----- No. 4 CRDL Potential Catalyst - Could Key Chart Support Be Growing At Multiple Levels? Take a look at CRDL's 6-month chart: Not only has CRDL doubled in valuation since early April, it has also moved above 3 of the most important technical chart lines. For two consecutive closes, CRDL has maintained above its: - 50-Day Simple Moving Average (SMA), its - 200-Day SMA, and its - 13-Day Exponential Moving Average. If support is growing at those levels, it could be HUGE moving forward for CRDL as it is already trading towards the upper right portion of its 6-month chart. Keep a close eye on these lines as CRDL looks to maintain this current bullish trend over the past several months. ----- CRDL Recap: New Nasdaq Alert Has Multiple Potential Breakout Catalysts To Watch Now No. 1 - Technical Indicators Triggered Bullish (10+ In All!) No. 2 - CRDL Plans To Reach Crucial Milestone Up To 6 Months Early No. 3 - Analysts Provide Positive Sentiment With Strong Price Targets No. 4 - Could Key Chart Support Be Growing At Multiple Levels? ----- Coverage is officially initiated on CRDL. When time allows, do this: Get CRDL on your radar right now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 9/20/23 and ending on 9/21/23 to publicly disseminate information about (CRDL) via Website, Email and SMS. SWN Media LLC was paid fifteen thousand USD via bank wire transfer. We own zero shares of (CRDL). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Electriq X LLC, TD Media LLC has been hired for a period beginning on 09/20/2022 and ending on 09/21/2022 to publicly disseminate information about (CRDL:US) (CRDL:CA) via digital communications. We have been paid an additional thirty thousand dollars USD. To date we have been paid eighty thousand dollars USD to disseminate information about (CRDL:US) (CRDL:CA) via digital communications. We own zero shares of (CRDL:US) (CRDL:CA). [( Fierce | 401 W. Atlantic Ave, Ste R10 Unit #271, Delray Beach, FL 33444 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net